biz.yahoo.com
IMI granted new U.S. patent for skin cholesterol technology
Wednesday January 8, 9:57 am ET
TORONTO, Jan. 8 /CNW/ - Predictive medicine company IMI International Medical Innovations Inc. (TSX:IMI - News) announced today that it has received a notice of allowance for a new U.S. patent that strengthens the company's intellectual property portfolio around skin cholesterol and coronary artery disease risk assessment. The patent is for a multi-layer analytical "thin film" that could lead to new film-based techniques for determining the amount of cholesterol in skin.
"As we get closer to commercializing our skin cholesterol products in the major world markets it is essential that we continue to enhance and expand our proprietary position on the technology," said Dr. Brent Norton, IMI President and CEO. "U.S. patents are the most important because of the relative size of the market. Our leadership position in skin cholesterol is further entrenched by this patent, now one of five different elements of our intellectual property portfolio in skin cholesterol."
"As innovators in the product development cycle a core component of our commercialization strategy is to add new patents on top of the existing patents we license from inventors. We're doing the same thing with our suite of cancer products to ensure they are well protected as we move them into the next phases of development," said Dr. Norton.
About IMI
IMI is a world leader in predictive medicine. IMI is dedicated to developing rapid, non-invasive tests for the early detection and monitoring of life-threatening diseases, particularly cardiovascular disease and cancer. IMI's lead product is a non-invasive skin test for coronary artery disease. IMI's cancer products in development include ColorectAlert(TM), a screening test for colorectal cancer, LungAlert(TM), a screening test for lung cancer, and a new test for breast cancer. For further information, please visit the company's web site at www.imimedical.com.
This release contains forward-looking statements that reflect the
company's current expectation regarding future events. The forward-looking
statements involve risk and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors
including, but not limited to, changing market conditions, successful and
timely completion of clinical studies, uncertainties related to the regulatory
approval process, establishment of corporate alliances and other risks
detailed from time to time in the company's quarterly filings.
For further information
Andrew Weir, Director, Communications (416) 222-3449 x27, aweir@imimedical.com
Richard Land, Karin Oloffson, Jaffoni & Collins Incorporated, (212) 835-8500 or imi@jcir.com |
